12
Views
15
CrossRef citations to date
0
Altmetric
Leading Article

Current Strategies to Reduce Cisplatin Toxicity

, , &

References

  • Gottlieb JA, Drewinko B. Review of the current clinical status of platinum coordination complexes in cancer chemotherapy. Cancer Chemother Rep 1975; 59: 621–628.
  • Madias NE, Harrington JT. Platinum nephrotoxicity. Am J Med 1978; 65: 307–314.
  • Higby DJ, Wallace HJ, Albert DJ, Holland JF. Diamminodichloroplatinum: a phase I study showing responses in testicular and other tumors. Cancer 1974; 33: 1219–1225.
  • Loeherer PJ, Einhorn L. Diagnosis and treatment. Drugs five years later: cisplatin. Ann Intern Med, 1984; 100: 704–713.
  • Livingston RB. Cisplatin in the treatment of solid tumors: effect of dose and schedule. JNCI 1989; 81:724–724.
  • Ozols RF. Cisplatin dose intensity. Sem Oncol, 1989; 16: 22–30.
  • Bruckner HW, Wallch R. High-dose cisplatinum for the treatment of refractory ovarian cancer. Gynecol Oncol, 1984; 12: 64–67.
  • Barker GH, Wiltshaw E. Use of high dose cis-dichloro-diammine platinum (II) following failure of previous chemotherapy for advanced carcinoma of the ovary. Br J Obstet Gynecol, 1981; 88: 1192–1199.
  • Chary KK, Higby DJ, Henderson ES, Swinerton KD. Phase I study of high dose cis-dichlorodiammineplatinum with forced diuresis. Cancer Treat Rep, 1977; 61: 367–370.
  • Hill JM, Loeb E, MacLellan A, Hill NO, Khan A, King JJ. Clinical studies of platinum coordination compounds in the treatment of various malignant disease. Cancer Chemother Rep, 1975; 59: 647–659.
  • Rosenberg B, VanCamp L. The successful treatment of large solid sarcoma 180 tumors by platinum compounds. Cancer Res, 1970; 30: 1799–1802.
  • Jacobs C, Bertino JR, Goffinet DR, Willard EF, Goode RL. 24-hour infusion of cis-platinum in head and neck cancers. Cancer, 1978; 42: 2135–2140.
  • Cvitkovic E. et al. Improvement of cis-dichlorodiammine platinum therapeutic index in an animal model. Cancer, 1977; 39: 1357–1361.
  • Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH. High dose cis-platinum diammine dichloride. Amelioration of renal toxicity by mannitol diuresis. Cancer, 1977; 39: 1372–1381.
  • Chary KK, Higby DJ, Henderson ES. A phase I study of high dose cis-diamminedichloroplatinum with forced diuresis. J Clin Haematol Oncol, 1977; 7: 633–641.
  • Einhorn LH, Williams SD. The role of cis-platinum in solid-tumor therapy. N Engl J Med, 1979; 100: 289–291.
  • Legha SS, Dimery IW. High -dose cisplatin administration without hypertonic saline: observation of disabling neurotoxicity. J Clin Oncol, 1985; 3: 1373–1378.
  • Litterst CL. Alteration in toxicity of cis-platinum. Toxicol Appl Pharm, 1981; 61: 99–108.
  • Ozols RF, Corden BJ. High dose cisplatin in hypertonic saline. Ann Intern Med, 1984; 100: 19–24.
  • Legha SD, Dimery I, Larson D, et al. Effect of hypertonic saline on the nephrotoxicity of cisplatin in patients with head and neck cancer. Proc Am Soc Clin Oncol 1984; 3:37 (abstr C-144).
  • Ozols RF, Ostchega Y, Myers CE, Young RC. High dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol, 1985; 3: 1246–1250.
  • Bajorin D, Bosl J, Fein R. Phase I trial escalating doses of cisplatin in hypertonic saline. J Clin Oncol, 1987; 5: 1589-1593.
  • Blumenreich MS, Woodcock TM et al. High dose cisplatin in patients with advanced malignancies. Cancer, 1985; 55: 1118–1122.
  • Howell SB, Pfeifle CG, Wung E et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med, 1982; 97: 845–851.
  • Gralla RJ, Loretta MI, Pisko SE, et al. Antiemtic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy induced nausea and vomiting. N Engl J Med, 1981; 305: 905-909.
  • Kris MG, Gralla RJ, Clark RA, Tyson LB. Dose-ranging evaluation of the serotonin antagonist GR-C507/75 when used as an antiemetic in patients receiving anticancer chemotherapy. J Clin Oncol, 1988; 6: 659–662.
  • Kris MG, Gralla RJ, Clark RA, Tyson LB. Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin. J Natl Cancer Inst, 1989; 81: 42–46.
  • Vermoken JB, Kapteijn TS, Hart AA. Cancer Clin Oncol, 1983; 19: 53–58.
  • Schweitzer VG, Dolan DF, Abrams GE, Davidson T, Snyder R. Amelioration of cisplatin induced ototoxicity by fosfomycin. Laryngology, 1986; 96: 948–958.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.